Korean Biotech Talks About U.S. Company Launch

Published on: June 29, 2018

Pharmaceutical Executive

Enzychem Lifesciences explains why the Korean biotech decided to open U.S. headquarters, as well as gives an update on their most recent clinical trials.

Enzychem Lifesciences’ Chairman and CEO, Ki-Young Sohn explains why the Korean biotech decided to open U.S. headquarters, as well as gives an update on their most recent clinical trials.

He spoke to Pharm Exec during a company event in New York City.